When biosimilars first started to gain significant momentum, with approvals and launches in Europe and later the US, big pharma interest in the sector soon grew. Major players like Amgen, Biogen, Boehringer Ingelheim, Merck and Pfizer all made moves into biosimilars, joining a market that also included established larger off-patent firms with the capacity to invest in biosimilars – such as Sandoz, Teva and Mylan – as well as a number of dedicated pure-play biosimilars developers.
However, over the years the landscape has evolved, with many originators now being more selective in their commitments to biosimilars...
